CLINICAL TRIAL: DOSE - AHF

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 本试验的假设是：1）通过随机分组至72小时血清肌酐的变化测量，低强度强化治疗策略引起的肾功能不全少于高强度强化治疗策略。 2)与“高强化”策略相比，“低强化”策略在缓解急性症状方面同样有效，如通过72小时内整体健康的系列视觉模拟评估曲线下面积所测量的。3)连续IV输注呋塞米比每日两次IV推注给药引起的肾功能不全更少，如通过肌酐从基线至72小时的变化所测量的。4)与每日两次推注给药相比，连续IV输注呋塞米在缓解急性症状方面更有效，如通过72小时内全球健康的系列视觉模拟评估曲线下面积所测量的。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The hypothesis of this trial is 1) That a low intensification strategy causes less renal dysfunction than a "high intensification strategy, as measured by change in serum creatinine from randomization to 72 hours. 2) That a "low intensification" strategy is equally efficacious in relieving acute symptoms compared to "high intensification" strategy, as measured by the area under the curve of serial visual analog assessments for global well being over 72 hours. 3) That continuous IV infusion of furosemide causes less renal dysfunction than twice daily IV bolus administration, as measured by change in creatinine from baseline to 72 hours. 4) That continuous IV infusion of furosemide is more efficacious at relieving acute symptoms compared to twice daily bolus administration, as measured by the area under the curve of serial visual analog assessments for global well being over 72 hours.